Business, energy, technology, markets and global industry news from Business News Today

glucocorticoids

PharmaDeviceNews glucocorticoids
Crenessity two-year data highlight growing interest in long-term congenital adrenal hyperplasia treatment, steroid reduction, and endocrine outcomes. Representative image.
Pharma & Biotech

Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia

See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.

Read More